Search

Can Eltrombopag help children with ITP say goodbye to bleeding?

Jun 13 2014 Posted in Press releases

Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Board elections

Shape the future of EHA by taking part in our 2025 Board election. Nominations closed on February 9, 2025. The ballot will open on April 8, 2025.

Long-lasting, late-onset, and chronic idiopathic neutropenia project

An SWG Grant-supported project initiated by EHA's SWG on Granulocytes and Constitutional Marrow Failure Disorders.

EHA Statement of Solidarity with Ukraine

Mar 01 2022 Posted in EHA's actions for Ukraine

The European Hematology Association (EHA) is deeply concerned about the situation in Ukraine, the plight of the civilian population, and the damage to healthcare infrastructures.

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Jun 12 2015

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.